Education
About Us
Working with TipRanks
Follow Us
Sedana Medical AB (SE:SEDANA)
:SEDANA
SEDANA Stock Chart & Stats
kr10.72
-kr0.18(-1.05%)
At close: 4:00 PM EST
kr10.72
-kr0.18(-1.05%)
Day’s Range― - ―
52-Week Rangekr6.65 - kr18.94
Previous CloseN/A
Volume45.94K
Average Volume (3M)247.68K
Market Cap
kr990.39M
Enterprise Valuekr864.27M
Total Cash (Recent Filing)kr90.98M
Total Debt (Recent Filing)kr6.58M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Apr 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained double-digit and multi-year revenue expansion indicates growing clinical adoption and market penetration. For a medtech with consumable ICU devices and a drug franchise, expanding sales build an installed base that drives recurring consumable revenue and strengthens long-term commercial scale.
Healthy Gross MarginsHigh gross margins (≈71%) imply attractive unit economics for devices and drug sales, enabling operating leverage as revenue grows. Durable margin structure supports future operating profitability once fixed costs and R&D are better absorbed by scale.
Low Leverage And Strong EquityA conservative balance sheet with minimal debt and substantial equity provides financial flexibility to fund commercialization, regulatory work and R&D. This lowers bankruptcy risk and allows the company to sustain cash burn during scaling without immediate refinancing pressure.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business consumes capital to grow rather than self-funds expansion. Continued cash burn increases reliance on external financing or equity raises, risking dilution or constrained investment in commercialization over the medium term.
Ongoing Net LossesDespite revenue growth, escalating net losses show the company has not converted sales into sustainable earnings. Continued losses pressure returns on capital and require either margin expansion or cost control to reach durable profitability within a 2–6 month strategic horizon.
Adoption & Regulatory DependenceCommercial success hinges on hospital adoption, payer reimbursement and regulatory approvals across markets. These structural external dependencies can slow rollout, limit addressable market capture, and introduce multi-regional timing risk that constrains predictable long-term revenue scaling.
Sedana Medical AB News
SEDANA FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was kr6.65 and its highest was kr18.94 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is kr990.39M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Apr 23, 2026 which is in 59 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.069 by -kr0.031.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is -0.03.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.069. Following the earnings report the stock price went up 11.715%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in SE:SEDANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---